BPC-157 Oral (Gut) vs Colostrum
A side-by-side research comparison of BPC-157 Oral (Gut) and Colostrum across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 Oral (Gut) | Colostrum |
|---|---|---|
| Full name | BPC-157 Oral (Stable Arginine Salt) | Bovine Colostrum (IgG-Rich) |
| Category | Gut Health | Gut Health |
| Status | Research compound | Dietary supplement (GRAS) |
| Mechanism | Upregulates VEGF and EGF receptors in GI mucosa, promotes angiogenesis at ulcer/lesion sites, modulates nitric oxide system, and interacts with dopamine and serotonin systems in the gut-brain axis. | IgG antibodies bind gut pathogens and endotoxins. Growth factors (EGF, TGF-β) stimulate epithelial cell proliferation and repair. Proline-rich polypeptides modulate Th1/Th2 balance for immune regulation. |
| Molecular weight | 1419 Da | Complex mixture |
| Half-life | ~4 hours (local GI transit) | IgG: ~2-4 hours in GI tract |
| Bioavailability | Limited systemic absorption; primary action is local GI | Oral - IgG survives gastric acid (~25-30%); growth factors act locally |
| Typical dose | 250-500 mcg | 5-20 g powder or 500-2000 mg capsules |
| Frequency | 2x daily on empty stomach | Daily on empty stomach |
| Route | Oral capsule or sublingual | Oral (powder or capsule) |
BPC-157 Oral (Gut) reported benefits
- Gastric ulcer healing
- Esophageal repair (GERD)
- Intestinal inflammation reduction
- IBD symptom relief
- Gut-brain axis support
- NSAID damage protection
Colostrum reported benefits
- Gut barrier repair
- IgG immune support
- Reduced gut inflammation
- Athletic recovery
- Reduced upper respiratory infections
- Growth factor delivery
Related comparisons
Research and educational reference only. Not medical advice.